Jun 03, 2020
American Regent Introduces Estradiol Valerate Injection, USP­; AO Rated and Therapeutically Equivalent to Delestrogen®1, 2
May 29, 2020
Sumitovant Biopharma Announces Myovant Sciences' Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine
Apr 16, 2020
Mayne Pharma Submits New Drug Application for E4/DRSP to the FDA
Jan 22, 2020
Theramex Acquires Commercial Rights for Oral Contraceptive Zoely
Dec 17, 2019
Prasco launches NuvaRing® (etonogestrel/ethinyl estradiol vaginal ring) Authorized Generic in the United States
Nov 13, 2019
Cassiopea Announces First Patient to be Enrolled in Phase II Trial for the Treatment of Androgenetic Alopecia in Females with Clascoterone Solution
Oct 02, 2019
Mayne Pharma Signs 20-Year Exclusive License and Supply Agreement for Novel Oral Contraceptive in the US
Sep 16, 2019
Exeltis USA, Inc. Announces the Launch of Slynd(TM)(drospirenone) tablets, 4 mg, the First and Only Progestin-Only Pill Providing Pregnancy Prevention with a 24-hour missed pill window and 24/4 Dosing Regimen
Jul 05, 2019
New Survey by ThickTails Among Women Reveals the Extent of Hair Loss During the Menopause
Jun 13, 2019
Contraceptives Market to Expand at a Healthy CAGR of 6.10%; Easy Availability of Contraceptive Devices to Propel Demand - TMR
Jun 06, 2019
Exeltis USA, Inc. Announces the Approval of Slynd(TM), the First and Only Progestin-Only Pill Providing Pregnancy Prevention with a 24/4 Dosing Regimen and 24-hour Missed Pill Window
Mar 25, 2019
Slayback Pharma announces approval of Hydroxyprogesterone Caproate Injection, USP 250 mg/ 1 mL in a single-dose vial, generic equivalent of Makena® Injection 250 mg/ 1 mL
Mar 14, 2019
Contraceptives: Opportunity Analysis and Forecasts to 2027
Feb 08, 2019
Hormonal Contraceptive Market to Touch US$ 30,930.5 Million by 2026, Says TMR
Jan 28, 2019
FSH Society Names Jamshid Arjomand, PhD, Chief Science Officer
Oct 22, 2018
The global human chorionic gonadotropin (hCG) market generated a revenue of $688 million in 2017 and is expected to reach $1,239 million by 2025, registering a CAGR of 7.6% from 2018 to 2025
Oct 10, 2018
Myovant Announces Presentation of Data from Phase 1 Trial of MVT-602 at 2018 American Society for Reproductive Medicine (ASRM) Annual Congress
Sep 28, 2018
Human Chorionic Gonadotropin (hCG) Market to Reach $1,239 Mn, Globally, by 2025 at 7.6% CAGR, Says Allied Market Research
Aug 21, 2018
Global Estrogen Therapeutics Market 2018-2022 - Evolution of Estrogen as a Therapeutic Target in Neurodevelopmental Disorders
Jan 24, 2018
Study: Hair Loss, Baldness, and Prostate Cancer are Linked; Lilac Corp Introduces Nolopecia, a Natural Remedy for Stimulating Hair Growth